<DOC>
	<DOCNO>NCT00043823</DOCNO>
	<brief_summary>Primary Objectives : 1 . ( Phase I ) To establish maximum tolerated dose dose-limiting toxicity combination OSI-774 ( Tarceva™ ) rhuMAb VEGF ( Avastin™ ) patient advance Non-small-cell lung carcinoma ( NSCLC ) . 2 . ( Phase II ) To assess response rate tolerability regimen dose level establish phase I portion study . Secondary Objectives : 1 . ( Phase I II ) To evaluate pharmacokinetic interaction combination . 2 . ( Phase I ) To establish phase II regimen OSI-774/ rhuMAb VEGF combination , study alone combination cytotoxic chemotherapy .</brief_summary>
	<brief_title>Avastin Tarceva Locally Advanced Metastatic Non-Squamous Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>Patients treat oral Tarceva daily 21 day cycle . Patients receive Avastin IV day 1 21-day cycle . If patient grade 3 4 toxicity 1st cycle , patient may continue dos Tarceva Avastin another cycle . If patient response stable disease 6 week ( 2 cycle ) , patient may continue dos Tarceva Avastin . A patient may receive treatment study one year , unless disease progress side effect become severe . The start dose 100 mg daily Tarceva 7.5 mg/kg every 21 day Avastin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient histologically proven stage IIIB pleural effusion , stage IV recurrent nonsquamous NSCLC . Patient Karnofsky performance status &gt; =70 % . Patient adequate bone marrow function : WBC &gt; = 3,000 cells/mm3 , ANC &gt; = 1,500 cells/mm3 , platelet count &gt; = 100,000 cells/mm3 , Hgb &gt; = 9.0 g/dL . Patient adequate liver function : total bilirubin level &lt; = 2.0 mg/dL , albumin &gt; = 2.5 g/dL . Transaminases ( aspartate aminotransferase ( AST SGOT ) and/or alanine aminotransferase ( ALT SGPT ) ) alkaline phosphatase may 2.5 x ULN . Patient adequate renal function : serum creatinine &lt; 2 mg/dl Patient sign write informed consent . Patient receive least one prior chemotherapeutic regimen recurrent metastatic disease . Patient receive prior chemotherapeutic regimen advance disease . Patient receive prior biologic therapy target epidermal growth factor receptor ( EGFR ) and/or Vascular endothelial growth factor ( VEGF ) . Patient receive radiation therapy within past 3 week . Patient sign symptom acute infection require systemic therapy . Patient exhibit confusion , disorientation , history major psychiatric illness may impair patient 's understanding informed consent . Patient require total parenteral nutrition lipid . Patient history uncontrolled heart disease and/or uncontrolled hypertension ( &gt; 150/100 mmHg ) . Because possible teratogenic effect , pregnant woman woman currently breastfeed may participate study . All woman childbearing potential must negative pregnancy test within 24 hour prior enrol study . Serious infection intercurrent illness require immediate therapy . Clinical/imaging evidence Central Nervous System ( CNS ) malignancy recently treat CNS malignancy , well experience recent cerebrovascular accident ( CVA ) , CNS bleeding . Pediatric patient open growth plate would expect . Urine protein qualitative value &gt; 30 urinalysis &gt; +1 proteinuria test dipstick . Patient clinical history coagulopathy thrombosis . Patient currently receive intend receive anticoagulant . Patient recent myocardial infarction ( still inside heal period ) . Note : sixmonth window optimal . Patient recover recent major surgery ( e.g. , less 2 week since surgery ) anticipate major surgery . Patient clinical history hemoptysis hematemesis . Patient may percutaneous endoscopic gastrostomy ( PEG ) gastrostomy ( G ) tube .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>rhuMAb VEGF</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Erlotinib Hydrocholoride</keyword>
</DOC>